Rubeosis iridis: preoperative iris fluorescein angiography and periocular steroids.
To study the risk of developing rubeosis iridis following vitrectomy, the use of preoperative iris fluorescein angiography was prospectively investigated on patients with diabetes mellitus, without any clinically detectable iris or angle neovascularization. With increasing severity of fluorescein leakage, the risk of iris neovascularization with or without glaucoma, six months after vitreous surgery, is significantly increased. It was also determined whether postoperative steroid therapy (periocular triamcinolone acetonide and topical prednisolone phosphate) reduces the risk of developing iris neovascularization after vitrectomy. Controlled and treated patient eyes did not differ significantly in the degree of rubeosis. However, neovascular glaucoma statistically occurred more frequently in the nonsteroid group.
D003930:Diabetic Retinopathy / Q000601:surgery*; D004359:Drug Therapy, Combination; D005451:Fluorescein Angiography; D005901:Glaucoma / Q000175:diagnosis / Q000517:prevention & control*; D006801:Humans; D007498:Iris / Q000098:blood supply*; D009389:Neovascularization, Pathologic / Q000175:diagnosis / Q000517:prevention & control*; D009883:Ophthalmic Solutions; D011182:Postoperative Care; D011183:Postoperative Complications / Q000175:diagnosis / Q000517:prevention & control; D011239:Prednisolone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014222:Triamcinolone Acetonide / Q000627:therapeutic use*; D014822:Vitreous Body / Q000601:surgery
D009883:Ophthalmic Solutions; C009022:prednisolone phosphate; D011239:Prednisolone; D014222:Triamcinolone Acetonide